SG11201405830VA - Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis - Google Patents
Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosisInfo
- Publication number
- SG11201405830VA SG11201405830VA SG11201405830VA SG11201405830VA SG11201405830VA SG 11201405830V A SG11201405830V A SG 11201405830VA SG 11201405830V A SG11201405830V A SG 11201405830VA SG 11201405830V A SG11201405830V A SG 11201405830VA SG 11201405830V A SG11201405830V A SG 11201405830VA
- Authority
- SG
- Singapore
- Prior art keywords
- prognosing
- diagnosing
- methods
- pulmonary fibrosis
- idiopathic pulmonary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616394P | 2012-03-27 | 2012-03-27 | |
US201261707411P | 2012-09-28 | 2012-09-28 | |
PCT/US2013/031178 WO2013148232A1 (en) | 2012-03-27 | 2013-03-14 | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201405830VA true SG11201405830VA (en) | 2014-10-30 |
Family
ID=49261043
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201405830VA SG11201405830VA (en) | 2012-03-27 | 2013-03-14 | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
SG10201702842SA SG10201702842SA (en) | 2012-03-27 | 2013-03-14 | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201702842SA SG10201702842SA (en) | 2012-03-27 | 2013-03-14 | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
Country Status (16)
Country | Link |
---|---|
US (2) | US20160230226A1 (en) |
EP (2) | EP2831280B1 (en) |
JP (1) | JP6404208B2 (en) |
KR (1) | KR102197524B1 (en) |
CN (2) | CN107099581B (en) |
AR (1) | AR090339A1 (en) |
AU (2) | AU2013240344A1 (en) |
BR (1) | BR112014023348A2 (en) |
CA (1) | CA2864884A1 (en) |
HK (1) | HK1206796A1 (en) |
IL (1) | IL256396A (en) |
MX (2) | MX370486B (en) |
NZ (1) | NZ628458A (en) |
RU (1) | RU2014139546A (en) |
SG (2) | SG11201405830VA (en) |
WO (1) | WO2013148232A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013035799A1 (en) | 2011-09-06 | 2013-03-14 | 株式会社シノテスト | Antibody capable of binding to specific region of periostin, and method for measuring periostin using same |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
JP6799201B2 (en) | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク. | Aerosol Tyrosine Kinase Inhibitor Compounds and Their Use |
BR112016008694A2 (en) * | 2013-10-23 | 2017-10-03 | Genentech Inc | METHODS FOR PREDICTING THE REACTION OF PATIENTS WITH ASTHMA, FOR PREDICTING THE ABILITY TO REACT IN PATIENTS WITH ASTHMA, FOR IDENTIFYING PATIENTS WITH ASTHMA, FOR TREATMENT OF PATIENTS WITH ASTHMA AND FOR TREATMENT OF ASTHMA, USE OF A KIT AND KIT |
JP6312054B2 (en) * | 2013-11-06 | 2018-04-18 | 学校法人日本大学 | Biomarker for interstitial pneumonia |
WO2015073912A1 (en) * | 2013-11-14 | 2015-05-21 | Wager Jeffrey | Treatment or prevention of pulmonary conditions with carbon monoxide |
CN106459898A (en) * | 2013-12-20 | 2017-02-22 | 哈佛大学校长及研究员协会 | Low shear microfluidic devices and methods of use and manufacturing thereof |
US9970935B2 (en) | 2014-02-06 | 2018-05-15 | The Brigham And Women's Hospital, Inc. | Uses of GLI1 in detecting tissue fibrosis |
TW201618795A (en) | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | Systems and methods to improve organ function and organ transplant longevity |
WO2015164716A1 (en) * | 2014-04-25 | 2015-10-29 | Brown University | Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome |
WO2015191841A1 (en) * | 2014-06-12 | 2015-12-17 | Yale University | Novel methods of treating or preventing fibrotic lung diseases |
EP2957634A1 (en) | 2014-06-20 | 2015-12-23 | Consejo Superior De Investigaciones Científicas | Compounds for prevention and/or treatment of fibrotic diseases |
JP7356788B2 (en) * | 2014-11-05 | 2023-10-05 | ベラサイト インコーポレイテッド | Systems and methods for diagnosing idiopathic pulmonary fibrosis in transbronchial biopsies using machine learning and high-dimensional transcriptional data |
CN104792998B (en) * | 2015-03-09 | 2016-06-08 | 中国人民解放军第四军医大学 | LOXL2 antigen is for preparing the application of thyroid carcinoma indication, invasion and attack, transfering reagent box |
CN106290892A (en) * | 2015-06-26 | 2017-01-04 | 上海市肿瘤研究所 | CTHRC1 application in liver cirrhosis diagnosis and treatment |
WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
EP3368512B1 (en) | 2015-10-27 | 2023-12-06 | Taipei Medical University | Indoline derivatives for treatment and/or prevention of fibrosis diseases |
CN105400870B (en) * | 2015-11-11 | 2018-09-25 | 南方医科大学 | Applications of the CD1c in bacterium the moon diagnosis of pulmonary tuberculosis |
BR112018010337A2 (en) * | 2015-11-23 | 2018-12-04 | Merck Patent Gmbh | anti-alpha-v integrin antibody for the treatment of fibrosis and / or fibrotic disorders |
US20190144547A1 (en) | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
WO2017203027A1 (en) * | 2016-05-27 | 2017-11-30 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
CN106319058B (en) * | 2016-08-31 | 2019-09-10 | 汪道文 | A kind of DNA library and its application detecting idiopathic pulmonary fibrosis Disease-causing gene |
AU2017324949B2 (en) * | 2016-09-07 | 2024-05-23 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
WO2018081236A1 (en) * | 2016-10-28 | 2018-05-03 | Cedars-Sinai Medical Center | Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy |
US20200017913A1 (en) * | 2017-03-02 | 2020-01-16 | President And Fellows Of Harvard College | Methods and systems for predicting treatment responses in subjects |
IT201700026858A1 (en) * | 2017-03-10 | 2018-09-10 | Univ Degli Studi Padova | USE OF INHIBITORS OF SERIN PROTEASIS, IN PARTICULAR OF SERPINB3 |
US20190127456A1 (en) * | 2017-10-31 | 2019-05-02 | Fibrogen, Inc. | Methods of treating idiopathic pulmonary fibrosis |
CN108931645A (en) * | 2018-07-26 | 2018-12-04 | 北京大学第医院 | A kind of HCV removes heptic fibrosis assessment system and appraisal procedure |
AU2019339260A1 (en) | 2018-09-10 | 2021-03-25 | Lung Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
EP3875958A4 (en) | 2018-10-29 | 2022-10-05 | National University Corporation Tokyo Medical and Dental University | Method for obtaining information on risk of reduced respiratory function in patient with interstitial pneumonia, and use thereof |
EP3908668A4 (en) * | 2019-01-11 | 2022-11-09 | University of Virginia Patent Foundation | Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis |
ES2957479A1 (en) * | 2022-06-07 | 2024-01-19 | Baigene S L | METHOD FOR OBTAINING USEFUL DATA FOR PREDICTING A SUBJECT'S RISK OF SUFFERING FIBROSIS (Machine-translation by Google Translate, not legally binding) |
CN115925920B (en) * | 2022-08-04 | 2023-07-25 | 瑞因细胞工程科技(广州)有限公司 | Method for treating liver cirrhosis by using genetically enhanced immune cells |
WO2024105446A1 (en) * | 2022-11-14 | 2024-05-23 | Alentis Therapeutics Ag | Biomarkers for fibrosis treatment using anti-claudin-1 antibodies |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (en) | 1990-08-29 | 1998-02-02 | Genpharm Int | Production and use of transgenic, non-human animals capable of forming heterologous antibodies |
ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
WO1993025788A1 (en) | 1992-06-09 | 1993-12-23 | Hoppe Ag | Latch and lockset system |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
DE19544393A1 (en) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistic herbicidal mixtures |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ES2301183T3 (en) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER. |
AR045614A1 (en) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | ANTIBODIES AGAINST THE RECEIVER OF INTERLEUQUINA- 1 AND USES OF THE SAME |
KR101627588B1 (en) * | 2003-12-23 | 2016-06-07 | 제넨테크, 인크. | Novel anti-il 13 antibodies and uses thereof |
US20080044420A1 (en) | 2005-05-11 | 2008-02-21 | Heavner George A | Anti-IL-13 antibodies, compositions, methods and uses |
SI1942939T2 (en) | 2005-09-30 | 2021-11-30 | Medimmune Limited | Interleukin-13 antibody composition |
EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
JP5030973B2 (en) * | 2006-01-13 | 2012-09-19 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Method for determining whether an IPF (idiopathic pulmonary fibrosis) patient is a candidate for oral tolerance treatment with type V collagen |
TWI395754B (en) * | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
EP2068920A2 (en) * | 2006-10-05 | 2009-06-17 | Centocor Ortho Biotech, Inc. | Ccr2 antagonists for treatment of fibrosis |
WO2008083695A1 (en) | 2006-12-20 | 2008-07-17 | Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH | Device and method for measuring the intensity of the light of a first group of light sources of a lighting unit |
CN101977935A (en) * | 2007-04-23 | 2011-02-16 | 惠氏公司 | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP3115469B1 (en) * | 2007-11-19 | 2020-04-29 | Celera Corporation | Lung cancer markers and uses thereof |
NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
WO2010028274A1 (en) * | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
US20110236380A1 (en) * | 2008-11-26 | 2011-09-29 | De Wildt Rudolf M T | Ligands that bind il-13 |
WO2010141469A2 (en) * | 2009-06-01 | 2010-12-09 | Case Western Reserve University | Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases |
EP3447491A3 (en) * | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
-
2013
- 2013-03-14 BR BR112014023348-9A patent/BR112014023348A2/en not_active IP Right Cessation
- 2013-03-14 MX MX2014011503A patent/MX370486B/en active IP Right Grant
- 2013-03-14 SG SG11201405830VA patent/SG11201405830VA/en unknown
- 2013-03-14 KR KR1020147029554A patent/KR102197524B1/en active IP Right Grant
- 2013-03-14 WO PCT/US2013/031178 patent/WO2013148232A1/en active Application Filing
- 2013-03-14 AU AU2013240344A patent/AU2013240344A1/en not_active Abandoned
- 2013-03-14 CN CN201611178102.8A patent/CN107099581B/en active Active
- 2013-03-14 EP EP13768451.0A patent/EP2831280B1/en active Active
- 2013-03-14 RU RU2014139546A patent/RU2014139546A/en not_active Application Discontinuation
- 2013-03-14 CN CN201380027564.8A patent/CN104334744A/en active Pending
- 2013-03-14 JP JP2015503288A patent/JP6404208B2/en active Active
- 2013-03-14 CA CA2864884A patent/CA2864884A1/en not_active Abandoned
- 2013-03-14 SG SG10201702842SA patent/SG10201702842SA/en unknown
- 2013-03-14 AR ARP130100827A patent/AR090339A1/en unknown
- 2013-03-14 NZ NZ628458A patent/NZ628458A/en not_active IP Right Cessation
- 2013-03-14 EP EP20153153.0A patent/EP3725892A1/en not_active Withdrawn
-
2014
- 2014-09-23 US US14/493,649 patent/US20160230226A1/en not_active Abandoned
- 2014-09-25 MX MX2019015159A patent/MX2019015159A/en unknown
-
2015
- 2015-08-03 HK HK15107420.8A patent/HK1206796A1/en unknown
-
2017
- 2017-12-18 IL IL256396A patent/IL256396A/en unknown
-
2018
- 2018-03-16 US US15/924,114 patent/US20190062836A1/en not_active Abandoned
- 2018-10-16 AU AU2018250393A patent/AU2018250393A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2831280A1 (en) | 2015-02-04 |
JP2015522246A (en) | 2015-08-06 |
NZ628458A (en) | 2016-11-25 |
JP6404208B2 (en) | 2018-10-10 |
CN107099581A (en) | 2017-08-29 |
IL256396A (en) | 2018-02-28 |
EP3725892A1 (en) | 2020-10-21 |
AU2018250393A1 (en) | 2018-11-08 |
CN107099581B (en) | 2021-07-13 |
KR20140143196A (en) | 2014-12-15 |
BR112014023348A2 (en) | 2019-03-19 |
KR102197524B1 (en) | 2020-12-31 |
AU2013240344A1 (en) | 2014-09-18 |
EP2831280B1 (en) | 2020-04-15 |
HK1206796A1 (en) | 2016-01-15 |
SG10201702842SA (en) | 2017-06-29 |
US20190062836A1 (en) | 2019-02-28 |
CN104334744A (en) | 2015-02-04 |
RU2014139546A (en) | 2016-05-20 |
CA2864884A1 (en) | 2013-10-03 |
US20160230226A1 (en) | 2016-08-11 |
EP2831280A4 (en) | 2016-02-24 |
MX2019015159A (en) | 2020-02-19 |
MX2014011503A (en) | 2014-12-05 |
MX370486B (en) | 2019-12-16 |
WO2013148232A1 (en) | 2013-10-03 |
AR090339A1 (en) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL256396A (en) | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis | |
HK1201298A1 (en) | Methods of diagnosing and treating idiopathic pulmonary fibrosis | |
EP2922861A4 (en) | Biomarker compositions and methods | |
EP2823306A4 (en) | Biomarker compositions and methods | |
EP2670866A4 (en) | Biomarkers and methods of use thereof | |
IL260115A (en) | Methods of treating fibrosis | |
EP2663864A4 (en) | Immunodiversity assessment method and its use | |
EP2928384A4 (en) | Tissue-captured anchors and methods of use | |
HK1209328A1 (en) | Compositions and methods for treating type iii gaucher disease iii | |
EP2844291A4 (en) | Methods for treating idiopathic pulmonary fibrosis | |
EP2731429A4 (en) | Compounds, methods of making, and methods of use | |
EP2888370A4 (en) | Methods for diagnosis, prognosis and methods of treatment | |
BR112014010288A2 (en) | methods, composition and refrigerator | |
EP2882447A4 (en) | Methods for diagnosing, prognosing and treating muscular dystrophy | |
EP2688901A4 (en) | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 | |
IL233588A0 (en) | Androecious cucurbitaceae, method of obtaining and using said cucurbitaceae | |
BR112015014884A2 (en) | method to identify, isolated polynucleotide and kit | |
HK1213495A1 (en) | Methods and compositions for treating and diagnosing acute myocardial infarction | |
EP2800568A4 (en) | Compositions, methods of use, and methods of treatment | |
HK1216891A1 (en) | Bryoid compositions, methods of making and use thereof | |
EP2673235A4 (en) | Soak and coke | |
ZA201405829B (en) | Cleaning arrangement and method of use | |
EP2937428A4 (en) | Lance, and fishing method using same | |
IL239426A0 (en) | Biomarker methods and compositions | |
HK1200093A1 (en) | Methods of treating melanoma with pak1 inhibitors pak1 |